Our Science
We produce our cellular product in-house, evaluate every batch against international guidelines and share what we learn openly, for our patients and for the medical community.
Our Approach
Auragens puts science and medicine first. We create our cellular product in our own laboratory, choose the administration method for each patient, and share our methods and research openly, because clearing up misinformation helps patients and moves the whole field forward.
Meet Our Chief Scientific Officer
Dr. James Utley, PhD, Chief Scientific Officer at Auragens, introduces Auracells™: the cells we use, how our laboratory evaluates them and why that matters for every patient we treat.
Optimizing Stem Cell Therapies
A proprietary process guides every batch of Auracells™ from expansion to release.
Advancing Regenerative Medicine
Our process explains how we work. The four cards below break down what we look for in every cell we use: its quality, its volume, its type and its safety.

Umbilical mesenchymal stem cells (hUC-MSCs) can be isolated from umbilical cord tissue, and their quality can be assessed against a range of criteria. At Auragens we follow ISCT guidelines and use only hUC-MSCs that we have thoroughly evaluated for purity, viability, multipotency, immunomodulatory capacity and capacity to expand.

Determining dose and protocol for hUC-MSCs requires specialized knowledge, and the right approach depends on the patient’s age, medical condition and goals. Cellular expansion potential matters because cells should expand in culture while maintaining their stem cell properties; our expansion methods support dosing specific to the individual patient and condition.

Wharton’s Jelly is the connective tissue surrounding the blood vessels of the umbilical cord. It is collected from donated cords after healthy, full-term births, a process that is non-invasive for mother and newborn and raises none of the ethical concerns associated with embryonic tissue.

Cells are processed at the Auragens Laboratory in a cGMP-grade ISO-7 cleanroom under ISCT guidelines, cryopreserved under controlled conditions and prepared per validated protocols at the point of care. Long-term safety data from large controlled trials are still emerging, and our medical team discusses the current evidence with every patient.
For the Medical Community
Research & Publications
Our physicians and scientists publish their work so patients and clinicians can review it for themselves.




Science FAQs
Auracells™, our umbilical cord–derived mesenchymal stem cells (hUC-MSCs) from Wharton’s Jelly, collected from donated umbilical cords after healthy, full-term births.
Every donor undergoes comprehensive health and infectious-disease testing against stringent criteria before any tissue is processed.
Each batch is characterized by flow cytometry immunophenotyping against ISCT minimal criteria for MSCs, positive for markers such as CD73, CD90 and CD105 and negative for hematopoietic markers such as CD34, CD45, CD11b, CD19 and HLA-DR, alongside viability and sterility testing.
In our own Auragens Laboratory, in a cGMP-grade ISO-7 cleanroom, under ISCT guidelines and AABB accreditation, in an FDA-registered laboratory.
Individually. Dose and protocol depend on the patient’s age, medical condition and treatment goals, and are set by our medical team.
Mesenchymal stem cell therapy is investigational for most of the conditions we evaluate and is not approved by the U.S. Food and Drug Administration as a standard treatment for them. Our medical team presents the current evidence, including its limitations, to every patient.
Yes. Clinicians and researchers are welcome to contact us to discuss our methods, data or a patient referral.
How to Get Started
Start with a candidacy review — no commitment required to find out where you stand.
Contact Us